Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-05), Bristol-Myers Squibb Co's 3-1 Month Momentum % is 2.07%.
The industry rank for Bristol-Myers Squibb Co's 3-1 Month Momentum % or its related term are showing as below:
BMY's 3-1 Month Momentum % is ranked better than 67.71% of 1022
companies
in the Drug Manufacturers industry
Industry Median: -7.035
vs BMY: 2.07
Bristol-Myers Squibb Co (NYSE:BMY) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Bristol-Myers Squibb Co 3-1 Month Momentum % Related Terms
BMY vs PFE, GILD, AMGN: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bristol-Myers Squibb Co 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Bristol-Myers Squibb Co's 3-1 Month Momentum % falls into.
Bristol-Myers Squibb Co (NYSE:BMY) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bristol-Myers Squibb Co (BMY) has a 3-1 Month Momentum % of 2.07% as of Aug. 05, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bristol-Myers Squibb Co and its competitors. According to the industry distribution chart, Bristol-Myers Squibb Co ranks #330 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 32.3%.
Is Bristol-Myers Squibb Co's 3-1 Month Momentum % too high?
Bristol-Myers Squibb Co's current 3-1 Month Momentum % is 2.07%. Based on the distribution chart, Bristol-Myers Squibb Co ranks #330 out of 1022 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bristol-Myers Squibb Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bristol-Myers Squibb Co's 3-1 Month Momentum % compare to PFE and GILD?
According to the Drug Manufacturers industry distribution chart, Bristol-Myers Squibb Co ranks #330 out of 1022 companies for 3-1 Month Momentum %. This puts Bristol-Myers Squibb Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Bristol-Myers Squibb Co and its competitors. Bristol-Myers Squibb Co's current 3-1 Month Momentum % is 2.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bristol-Myers Squibb Co stock overvalued right now?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co (BMY) is currently considered Modestly Overvalued. The stock's GF Value™ is $56.34, compared to a current price of $63.63 — trading 12.9% above its estimated fair value. The current 3-1 Month Momentum % is 2.07%. Bristol-Myers Squibb Co's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Bristol-Myers Squibb Co (BMY), the current 3-1 Month Momentum % is 2.07% as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bristol-Myers Squibb Co (BMY) Overvalued in 2026?
Based on GuruFocus' analysis, Bristol-Myers Squibb Co stock appears to be overvalued.
The current stock price of $63.63 is trading 12.9% above its estimated GF Value™ of $56.34.
GuruFocus considers Bristol-Myers Squibb Co to be Modestly Overvalued.
Key valuation signals for BMY:
3-1 Month Momentum %: 2.07%
GF Value™: $56.34 vs. price of $63.63 (12.9% above fair value)
No single metric tells the full story. See the BMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
71GF Score
Get the complete analysis for BMY
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMY has been successfully added to your 
